SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR l5(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) February 1, 1999
----------------
NORTH AMERICAN VACCINE, INC.
-----------------------------------------------------
(Exact name of registrant as specified in its charter)
CANADA 1-10451 98-0121241
- ---------------------------- ----------- -----------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File number) Identification No)
10150 Old Columbia Road, Columbia, Maryland 21046
- --------------------------------------------------
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code 410-309-7100
------------
- -------------------------------------------------------------
(Former name or former address, if changed since last report)
<PAGE>
ITEM 5 OTHER EVENTS
- ------ ------------
On February 1, 1999, North American Vaccine announced that it has received
notification that the German regulatory authorities have issued a national
marketing authorization for the company's combined diphtheria, tetanus,
acellular pertussis and inactivated injectable polio ("DTaP-IPV") vaccine. Under
the German marketing authorization, the DTaP-IPV vaccine will be utilized for
active immunization against diphtheria, tetanus, pertussis (whooping cough) and
polio in infants. The DTaP-IPV will be marketed and distributed in Germany by
Chiron Behring, under the terms of an existing distribution agreement.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NORTH AMERICAN VACCINE, INC.
----------------------------
(Registrant)
By /s/ Randal Chase
---------------------------
Name: Randal Chase, Ph.D.
Title: President and Chief Executive Officer
Date: February 1, 1999
3
